Biolase Company Profile (NASDAQ:BIOL)

About Biolase (NASDAQ:BIOL)

Biolase logoBIOLASE, Inc. (BIOLASE) is a medical device company that develops, manufactures, markets and sells laser systems in dentistry and medicine. The Company markets, sells, and distributes dental imaging equipment, including cone beam digital x-rays and computer-aided design (CAD)/computer-aided manufacturing (CAM) intra-oral scanners, in-office, chair-side milling machines and three-dimensional (3-D) printers. It offers two categories of laser system products: WaterLase (all-tissue) systems and Diode (soft tissue) systems. Its brand, WaterLase, uses a combination of water and laser energy to perform procedures performed using drills, scalpels, and other traditional dental instruments for cutting soft and hard tissue. It also offers its Diode laser systems to perform soft tissue, pain therapy, and cosmetic procedures, including teeth whitening. Its Waterlase and Diode systems use disposable laser tips of differing sizes and shapes depending on the procedures being performed.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Advanced Medical Equipment & Technology
  • Sub-Industry: N/A
  • Symbol: NASDAQ:BIOL
  • CUSIP: N/A
  • Web: www.biolase.com
Capitalization:
  • Market Cap: $41.03 million
  • Outstanding Shares: 75,976,000
Average Prices:
  • 50 Day Moving Avg: $0.61
  • 200 Day Moving Avg: $1.01
  • 52 Week Range: $0.48 - $1.98
P/E:
  • Trailing P/E Ratio: N/A
  • P/E Growth: -0.1800
Sales & Book Value:
  • Annual Revenue: $50.48 million
  • Price / Sales: 0.85
  • Book Value: $0.33 per share
  • Price / Book: 1.70
Profitability:
  • EBIDTA: ($14,680,000.00)
  • Net Margins: -31.64%
  • Return on Equity: -64.44%
  • Return on Assets: -35.66%
Debt:
  • Current Ratio: 2.21%
  • Quick Ratio: 1.23%
Misc:
  • Average Volume: 143,783 shs.
  • Beta: 2.26
  • Short Ratio: 16.73
 

Frequently Asked Questions for Biolase (NASDAQ:BIOL)

What is Biolase's stock symbol?

Biolase trades on the NASDAQ under the ticker symbol "BIOL."

How were Biolase's earnings last quarter?

Biolase, Inc. (NASDAQ:BIOL) issued its quarterly earnings results on Monday, August, 7th. The company reported ($0.06) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.02) by $0.04. The business earned $12.61 million during the quarter. Biolase had a negative return on equity of 64.44% and a negative net margin of 31.64%. View Biolase's Earnings History.

When will Biolase make its next earnings announcement?

Biolase is scheduled to release their next quarterly earnings announcement on Monday, November, 6th 2017. View Earnings Estimates for Biolase.

Where is Biolase's stock going? Where will Biolase's stock price be in 2017?

1 brokers have issued 12 month price objectives for Biolase's stock. Their forecasts range from $2.50 to $2.50. On average, they anticipate Biolase's share price to reach $2.50 in the next year. View Analyst Ratings for Biolase.

Who are some of Biolase's key competitors?

Who are Biolase's key executives?

Biolase's management team includes the folowing people:

  • Jonathan T. Lord M.D., Chairman of the Board
  • Harold C. Flynn Jr., President, Chief Executive Officer
  • Brendan O'Connell, Vice President - Finance and Corporate Controller
  • Holger Arens, Vice President, Managing Director of Europe, the Middle East and Africa
  • James D. Surek, Vice President - Sales, Americas
  • Michael Roux, Vice President of Marketing
  • Matthew Wilson, Vice President of Human Resources
  • Samuel B. Low, Vice President - Dental and Clinical Affairs, Chief Dental Officer
  • George W. Bickerstaff III, Director
  • Paul N. Clark, Director

Who owns Biolase stock?

Biolase's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (2.23%), Birchview Capital LP (1.90%), Granite Investment Partners LLC (1.41%), Trellus Management Company LLC (0.52%), Teton Advisors Inc. (0.50%) and California Public Employees Retirement System (0.18%). Company insiders that own Biolase stock include David C Dreyer, Jack W Schuler, Larry N Feinberg and Paul N Clark. View Institutional Ownership Trends for Biolase.

Who sold Biolase stock? Who is selling Biolase stock?

Biolase's stock was sold by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Granite Investment Partners LLC and Princeton Capital Management Inc.. View Insider Buying and Selling for Biolase.

Who bought Biolase stock? Who is buying Biolase stock?

Biolase's stock was bought by a variety of institutional investors in the last quarter, including Trellus Management Company LLC. Company insiders that have bought Biolase stock in the last two years include David C Dreyer, Jack W Schuler, Larry N Feinberg and Paul N Clark. View Insider Buying and Selling for Biolase.

How do I buy Biolase stock?

Shares of Biolase can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Biolase's stock price today?

One share of Biolase stock can currently be purchased for approximately $0.57.


MarketBeat Community Rating for Biolase (NASDAQ BIOL)
Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  57 (Vote Outperform)
Underperform Votes:  36 (Vote Underperform)
Total Votes:  93
MarketBeat's community ratings are surveys of what our community members think about Biolase and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Biolase (NASDAQ:BIOL) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Buy Rating
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $2.50 (341.46% upside)

Analysts' Ratings History for Biolase (NASDAQ:BIOL)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
4/25/2017Singular ResearchInitiated CoverageBuy$2.50LowView Rating Details
(Data available from 9/21/2015 forward)

Earnings

Earnings History for Biolase (NASDAQ:BIOL)
Earnings by Quarter for Biolase (NASDAQ:BIOL)
Earnings History by Quarter for Biolase (NASDAQ BIOL)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/6/2017($0.04)N/AView Earnings Details
8/7/2017Q2 2017($0.02)($0.06)$12.61 millionViewListenView Earnings Details
5/3/2017Q1 2017($0.03)($0.06)$10.87 millionViewListenView Earnings Details
3/8/2017Q4 2016$0.02($0.06)$13.76 millionViewListenView Earnings Details
11/8/2016Q316($0.02)($0.05)$12.40 million$13.20 millionViewListenView Earnings Details
5/9/2016Q116($0.03)($0.07)$11.90 million$11.00 millionViewN/AView Earnings Details
3/9/2016Q415($0.09)($0.04)$13.90 million$14.50 millionViewN/AView Earnings Details
11/4/2015Q315($0.08)($0.09)$1.50 million$11.20 millionViewN/AView Earnings Details
11/4/2014Q314($0.09)($0.08)$11.70 million$12.70 millionViewN/AView Earnings Details
8/7/2014Q214($0.08)($0.17)$12.97 million$10.20 millionViewN/AView Earnings Details
5/12/2014Q114($0.05)($0.11)$13.29 million$11.50 millionViewN/AView Earnings Details
3/5/2014Q413($0.04)($0.04)$15.67 million$15.20 millionViewN/AView Earnings Details
11/5/2013Q313($0.05)($0.10)$16.42 million$12.30 millionViewN/AView Earnings Details
8/7/2013Q2 2013($0.04)($0.06)$15.69 million$14.20 millionViewListenView Earnings Details
5/7/2013Q1 2013($0.01)($0.06)$14.48 million$14.60 millionViewN/AView Earnings Details
3/6/2013Q4 2012$0.05$18.03 million$19.10 millionViewListenView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Biolase (NASDAQ:BIOL)

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Biolase (NASDAQ:BIOL)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Biolase (NASDAQ:BIOL)
Insider Ownership Percentage: 7.10%
Institutional Ownership Percentage: 37.34%
Insider Trades by Quarter for Biolase (NASDAQ:BIOL)
Institutional Ownership by Quarter for Biolase (NASDAQ:BIOL)
Insider Trades by Quarter for Biolase (NASDAQ:BIOL)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
2/18/2016Jack W SchulerMajor ShareholderBuy500$0.80$400.00View SEC Filing  
2/17/2016Jack W SchulerMajor ShareholderBuy4,100$0.80$3,280.00View SEC Filing  
2/12/2016Jack W SchulerMajor ShareholderBuy19,080$0.76$14,500.80View SEC Filing  
2/10/2016Jack W SchulerMajor ShareholderBuy67,213$0.78$52,426.14View SEC Filing  
1/25/2016Jack W SchulerMajor ShareholderBuy1,400$0.80$1,120.00View SEC Filing  
1/22/2016Jack W SchulerMajor ShareholderBuy6,670$0.78$5,202.60View SEC Filing  
1/20/2016Jack W SchulerMajor ShareholderBuy24,200$0.75$18,150.00View SEC Filing  
12/28/2015Jack W SchulerMajor ShareholderBuy18,350$0.79$14,496.50View SEC Filing  
12/24/2015Jack W SchulerMajor ShareholderBuy41,900$0.76$31,844.00View SEC Filing  
12/22/2015Jack W SchulerMajor ShareholderBuy87,200$0.74$64,528.00View SEC Filing  
12/21/2015Jack W SchulerMajor ShareholderBuy127,892$0.73$93,361.16View SEC Filing  
12/17/2015Jack W SchulerMajor ShareholderBuy34,158$0.70$23,910.60View SEC Filing  
11/11/2015Larry N FeinbergMajor ShareholderBuy54,800$0.79$43,292.00View SEC Filing  
11/10/2015Paul N ClarkDirectorBuy134,579$0.75$100,934.25View SEC Filing  
9/24/2015David C DreyerCFOBuy5,000$1.20$6,000.00View SEC Filing  
9/22/2015David C DreyerCFOBuy5,000$1.37$6,850.00View SEC Filing  
9/17/2015David C DreyerCFOBuy10,000$1.45$14,500.00View SEC Filing  
11/3/2014Jeffrey M NugentCEOBuy40,465$2.39$96,711.35View SEC Filing  
11/3/2014Jonathan T Md LordDirectorBuy101,163$2.39$241,779.57View SEC Filing  
11/3/2014Larry N FeinbergMajor ShareholderBuy2,067,979$2.39$4,942,469.81View SEC Filing  
7/22/2014Alexander K ArrowCOOBuy7,812$1.92$14,999.04View SEC Filing  
7/22/2014Frederick D FurryCFOBuy13,020$1.92$24,998.40View SEC Filing  
7/22/2014Jeffrey M NugentCEOBuy52,083$1.92$99,999.36View SEC Filing  
7/22/2014Paul N ClarkDirectorBuy520,833$1.92$999,999.36View SEC Filing  
7/18/2014Larry N FeinbergMajor ShareholderBuy2,270,836$1.92$4,360,005.12View SEC Filing  
2/12/2014Larry N FeinbergMajor ShareholderBuy2,035,033$2.57$5,230,034.81View SEC Filing  
1/31/2014Larry Feinbergmajor shareholderBuy30,798$2.45$75,455.10View SEC Filing  
12/19/2013Larry Feinbergmajor shareholderBuy340,000$1.80$612,000.00View SEC Filing  
12/17/2013Larry Feinbergmajor shareholderBuy150,400$1.87$281,248.00View SEC Filing  
8/23/2012Frederick D FurryCFOBuy5,075$1.64$8,323.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Biolase (NASDAQ:BIOL)
Latest Headlines for Biolase (NASDAQ:BIOL)
Source:
DateHeadline
finance.yahoo.com logoETFs with exposure to BIOLASE, Inc. : September 6, 2017
finance.yahoo.com - September 5 at 11:15 PM
finance.yahoo.com logoBIOLASE Names Jonathan T. Lord Chairman of the Board
finance.yahoo.com - September 5 at 6:10 PM
americanbankingnews.com logoLeMaitre Vascular (LMAT) and Biolase (BIOL) Head-To-Head Review
www.americanbankingnews.com - September 2 at 4:10 PM
finance.yahoo.com logoETFs with exposure to BIOLASE, Inc. : August 25, 2017
finance.yahoo.com - August 25 at 6:18 PM
finanznachrichten.de logoGlobsl $10 Billion Dental Diagnostics & Surgical Equipments Products Markets, 2022
www.finanznachrichten.de - August 17 at 5:55 PM
finance.yahoo.com logoBIOLASE, Inc. :BIOL-US: Earnings Analysis: Q2, 2017 By the Numbers : August 16, 2017
finance.yahoo.com - August 16 at 5:05 PM
prnewswire.com logoGlobal Dental Diagnostics & Surgical Equipments Market, Company Analysis & Forecast to 2024
www.prnewswire.com - August 14 at 9:59 PM
americanbankingnews.com logoContrasting Dextera Surgical (DXTR) and Biolase (NASDAQ:BIOL)
www.americanbankingnews.com - August 11 at 3:08 PM
finance.yahoo.com logoEdited Transcript of BIOL earnings conference call or presentation 7-Aug-17 8:30pm GMT
finance.yahoo.com - August 8 at 9:42 PM
finance.yahoo.com logoETFs with exposure to BIOLASE, Inc. : August 8, 2017
finance.yahoo.com - August 8 at 4:20 PM
americanbankingnews.com logoBiolase, Inc. (BIOL) Releases Earnings Results, Misses Estimates By $0.04 EPS
www.americanbankingnews.com - August 8 at 12:28 PM
finance.yahoo.com logoBiolase reports 2Q loss
finance.yahoo.com - August 7 at 10:05 PM
finance.yahoo.com logoBIOLASE Reports 2017 Second Quarter and Six-Month Results
finance.yahoo.com - August 7 at 5:04 PM
americanbankingnews.com logoBiolase (NASDAQ:BIOL) & Agilent Technologies (A) Head-To-Head Comparison
www.americanbankingnews.com - August 2 at 8:10 AM
finance.yahoo.com logoBIOLASE® to Host 2017 Second Quarter Financial Results Conference Call on August 7
finance.yahoo.com - July 31 at 4:34 PM
reuters.com logoBRIEF-Biolase Inc files for resale of up to 12 million shares
www.reuters.com - July 22 at 9:30 PM
finance.yahoo.com logoETFs with exposure to BIOLASE, Inc. : July 13, 2017
finance.yahoo.com - July 13 at 5:34 PM
streetinsider.com logoForm 4 BIOLASE, INC For: Jun 30 Filed by: MOLL FREDERIC H
www.streetinsider.com - July 4 at 8:26 PM
streetinsider.com logoForm 4 BIOLASE, INC For: Jun 30 Filed by: CLARK PAUL N
www.streetinsider.com - July 4 at 2:43 AM
finance.yahoo.com logoETFs with exposure to BIOLASE, Inc. : June 26, 2017
finance.yahoo.com - June 26 at 4:31 PM
prnewswire.com logoMedical Lasers Market Size is Projected to be Around $13 Billion by 2025: Crystal Market Research
www.prnewswire.com - June 20 at 4:38 PM
seekingalpha.com logoBIOLASE (BIOL) Presents At 7th Annual LD Micro Invitational Conference - Slideshow
seekingalpha.com - June 8 at 4:44 PM
americanbankingnews.com logoReviewing EnteroMedics (ETRM) and BIOLASE (BIOL)
www.americanbankingnews.com - June 6 at 2:06 PM
finance.yahoo.com logoBIOLASE to Present at the 7th Annual LD Micro Invitational
finance.yahoo.com - May 31 at 10:35 AM
finance.yahoo.com logoETFs with exposure to BIOLASE, Inc. : May 22, 2017
finance.yahoo.com - May 22 at 3:52 PM
americanbankingnews.com logoShort Interest in BIOLASE Inc (BIOL) Drops By 1.4%
www.americanbankingnews.com - May 13 at 7:08 PM
finance.yahoo.com logoETFs with exposure to BIOLASE, Inc. : May 11, 2017
finance.yahoo.com - May 11 at 4:28 PM
finance.yahoo.com logoBIOLASE, Inc. :BIOL-US: Earnings Analysis: Q1, 2017 By the Numbers : May 9, 2017
finance.yahoo.com - May 9 at 3:56 PM
finance.yahoo.com logoBIOLASE Announces Management Change
finance.yahoo.com - May 5 at 3:56 PM
americanbankingnews.com logoBIOLASE Inc (BIOL) Posts Quarterly Earnings Results, Misses Estimates By $0.03 EPS
www.americanbankingnews.com - May 4 at 9:00 PM
finance.yahoo.com logoEdited Transcript of BIOL earnings conference call or presentation 3-May-17 8:30pm GMT
finance.yahoo.com - May 4 at 4:03 PM
finance.yahoo.com logoBIOLASE Reports 2017 First Quarter Results
finance.yahoo.com - May 3 at 6:14 PM
marketbeat.com logoBiolase reports 1Q loss
marketbeat.com - May 3 at 6:05 PM
americanbankingnews.com logoSomewhat Favorable Media Coverage Somewhat Likely to Impact BIOLASE (BIOL) Share Price
www.americanbankingnews.com - May 2 at 11:26 PM
americanbankingnews.com logoBIOLASE Inc (BIOL) Scheduled to Post Quarterly Earnings on Wednesday
www.americanbankingnews.com - May 1 at 1:18 PM
americanbankingnews.com logoBIOLASE (BIOL) Earning Somewhat Favorable News Coverage, Report Finds
www.americanbankingnews.com - April 26 at 2:32 PM
finance.yahoo.com logoBIOLASE® to Host 2017 First Quarter Financial Results Conference Call on May 3
finance.yahoo.com - April 26 at 12:27 PM
americanbankingnews.com logoBIOLASE Inc (BIOL) Coverage Initiated at Singular Research
www.americanbankingnews.com - April 25 at 3:06 PM
streetinsider.com logoForm 4 BIOLASE, INC For: Apr 18 Filed by: LORD JONATHAN T MD
www.streetinsider.com - April 19 at 9:14 PM
americanbankingnews.com logoBIOLASE (BIOL) Earning Somewhat Favorable Media Coverage, Report Finds
www.americanbankingnews.com - April 17 at 5:25 PM
americanbankingnews.com logoBIOLASE (BIOL) Earning Positive News Coverage, Report Shows
www.americanbankingnews.com - April 14 at 5:40 PM
finance.yahoo.com logoBIOLASE to Raise $10.5 Million from Institutional and Individual Investors in a Private Placement
finance.yahoo.com - April 13 at 4:03 PM
bizjournals.com logoREGISTER TODAY: Multidisciplinary Treatment Solutions for Peri-Implantitis Symposium
www.bizjournals.com - April 7 at 3:52 PM
uk.finance.yahoo.com logoBIOLASE to Showcase Two New Game-Changing Products at International Dental Show in Cologne
uk.finance.yahoo.com - March 20 at 11:08 AM
finance.yahoo.com logoBIOLASE, INC Financials
finance.yahoo.com - March 16 at 3:22 PM
finance.yahoo.com logoBIOLASE Announces Inducement Grant under NASDAQ Listing Rule 5635(c)(4)
finance.yahoo.com - March 14 at 8:41 AM
finance.yahoo.com logoBIOLASE Names James D. Surek Vice President Sales, Americas
finance.yahoo.com - March 13 at 11:12 AM
biz.yahoo.com logoBIOLASE, INC Files SEC form 10-K, Annual Report
biz.yahoo.com - March 10 at 4:44 PM
finance.yahoo.com logoBIOLASE to Present at the 29th Annual ROTH Conference
finance.yahoo.com - March 9 at 4:27 PM
reuters.com logoBRIEF-Biolase Q4 loss per share $0.07
www.reuters.com - March 9 at 2:42 AM

Social

Chart

Biolase (BIOL) Chart for Thursday, September, 21, 2017

This page was last updated on 9/21/2017 by MarketBeat.com Staff